BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioNTech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BioNTech's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06107686-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06107686)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Selected Patients With Advanced Solid Tumors\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06107686
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05879055-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pumitamig: Phase 2 readout est. (NCT05879055)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Study of PM8002 in Combination W
 ith Chemotherapy in Patients With NEN\nEstimated primary completion: 1 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 9055
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202364-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT07202364)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Patients With Advanced Solid Tumors\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07202364
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133750-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07133750)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: PM8002 (BNT327) in Combination Wit
 h Chemotherapy in Patients With Metastatic Colorectal Cancer\nEstimated pr
 imary completion: May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07133750
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616532-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06616532)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: PM8002 in
  Combination With Paclitaxel Compared With Chemotherapy as Second-line Tre
 atment in Small Cell Lung Cancer\nEstimated primary completion: May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06616532
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449209-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06449209)
DESCRIPTION:Pumitamig\, phase 2\, Small Cell Lung Cancer.\nStudy: Safety\, 
 Preliminary Effectiveness of BNT327\, an Investigational Therapy for Patie
 nts With Small-cell Lung Cancer in Combination With Chemotherapy\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06449209
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419621-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06419621)
DESCRIPTION:Pumitamig\, phase 3.\nStudy: PM8002 or Placebo Plus Nab-Paclita
 xel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06419621
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439771-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06439771)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase 2 Study to Evaluate the Efficacy\, Safety and Pharm
 acokinetics of YL202 in Patients With BC\nEstimated primary completion: 30
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beruzatat
 ug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06439771
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05150691-2448@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT05150691)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05150691
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438329-2449@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Sacituzumab drozuntecan: Phase 1/2 readout est. (NCT05438329)
DESCRIPTION:Sacituzumab drozuntecan\, phase 1/2.\nStudy: First-in-human Stu
 dy of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors\nEstimated prima
 ry completion: 13 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05438329
URL:https://assetmemo.bio/drug/sacituzumab-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147348-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07147348)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A First-in-human\, Dose Escalati
 on and Indication Expansion Study of BNT3212 as Monotherapy or in Combinat
 ion With BNT327 in Adults With Advanced Solid Tumors\nEstimated primary co
 mpletion: November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07147348
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05914116-2414@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elfetabart drozuntecan: Phase 1/2 readout est. (NCT05914116)
DESCRIPTION:Elfetabart drozuntecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05914116
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255404-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07255404)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Clinical Trial Testing the Safet
 y of Pumitamig (an Investigational Drug) and How Well it Works When Combin
 ed With Chemotherapy for People Who Have Not Been Treated Yet for Pancreat
 ic Cancer\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07255404
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265428-2448@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06265428)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265428
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461454-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07461454)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: YL202 Versus Treatment of Physician's Choice in Patients Wi
 th HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7461454
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297212-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07297212)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Clinical Trial Testing the Safet
 y of the Investigational Drug Pumitamig (BNT327) and How Well it Works in 
 Patients With Recurrent Glioblastoma\nEstimated primary completion: Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729721
 2
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070232-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Beruzatatug pelitecan: Phase 1/2 readout est. (NCT07070232)
DESCRIPTION:Beruzatatug pelitecan\, phase 1/2.\nStudy: A Clinical Study to 
 Test if an Investigational Treatment Called BNT326 is Safe and Potentially
  Beneficial When Used Alone or in Combination With Other Investigational T
 reatments Such as BNT327\, for People With Advanced Malignant Tumors\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07070232
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340568-2448@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06340568)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, Endometrial Cancer.\nStudy: 
 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy 
 or Chemotherapy in Patients With Recurring Uterine Cancer\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06340568
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871214-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07871214)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Assess The Safety and Tolerability of Pumitamig-Based Therapy Admini
 stered Before Surgery in Participants With Early-Stage Non-Small Cell Lung
  Cancer (ROSETTA Lung-220)\nEstimated primary completion: 15 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07871214
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160725-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07160725)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Phase 1/2a\, First-in-human\, 
 Study of BMS-986517 in Participants With Advanced Solid Tumors\nEstimated 
 primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07160725
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449222-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06449222)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: Safety and Preliminary Effectivene
 ss of BNT327\, an Investigational Therapy for Breast Cancer\, When Given i
 n Combination With Chemotherapy\nEstimated primary completion: August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06449222
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Study of Navlimetostat (BMS-9865
 04) Monotherapy and in Combination With Other Agents in Participants With 
 Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (Mou
 ntainTAP-5)\nEstimated primary completion: 15 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416994-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07416994)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With L
 ocally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: 31 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07416994
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892548-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06892548)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Investigate 
 the Efficacy and Safety of an Investigational Combination Therapy With BNT
 324 and BNT327 in Patients With Advanced Lung Cancer\nEstimated primary co
 mpletion: September 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06892548
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07680764)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy To Assess the Safety\, Tolerability\, and Efficacy of Imzokitug in Comb
 ination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pum
 itamig and PDCT as First-line Treatment for Participants With Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841055-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06841055)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Preliminary Efficacy of Pumitamig (BNT327)\, an Investigational Ther
 apy for Patients With Non-small Cell Lung Cancer in Combination With Chemo
 therapy as First-line or Second-line Treatment\nEstimated primary completi
 on: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pum
 itamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06841055
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111520-1982@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Beruzatatug pelitecan: Phase 1/2 readout est. (NCT07111520)
DESCRIPTION:Beruzatatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Trial to Test if an Investigational Combination Therap
 y With BNT326 and BNT327 is Safe and Potentially Beneficial for People Wit
 h Advanced Non-small Cell Lung Cancer (NSCLC)\nEstimated primary completio
 n: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 uzatatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07111520
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712316-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT06712316)
DESCRIPTION:Pumitamig\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety\, Efficacy\, and Pharmacokinetics of BNT327 in Combination With Chemot
 herapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)\
 nEstimated primary completion: January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06712316
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697197-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06697197)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Study of BMS-986482 Alone or a
 s Combination Therapy in Participants With Advanced Solid Tumors\nEstimate
 d primary completion: 4 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06697197
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712355-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06712355)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: Safety an
 d Efficacy of BNT327\, an Investigational Therapy in Combination With Chem
 otherapy for Patients With Untreated Small-cell Lung Cancer\nEstimated pri
 mary completion: April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06712355
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325136-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07325136)
DESCRIPTION:Pumitamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Assess the Safety and Tolerability of BMS-986525 Alone and in Combinat
 ion Therapy in Participants With Relapsed/Refractory Small Cell Lung Cance
 r\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07325136
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827236-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06827236)
DESCRIPTION:Pumitamig\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Clinical Study to Find the Optimal Dose of an Investigational Treat
 ment Called BNT323 When Used in Combination With Another Investigational T
 reatment\, BNT327\, and to Test if That Combination Treatment is Safe and 
 Beneficial for Patients With Advanced Breast Cancer\nEstimated primary com
 pletion: August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06827236
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291076-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07291076)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Study to Evaluate the Safety a
 nd Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Pa
 rticipants With First-Line Advanced or Unresectable Hepatocellular Carcino
 ma (HCC) (ROSETTA HCC-206)\nEstimated primary completion: 15 October 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07291076
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, and Efficacy of Pumitamig Alone or in Combination With Oth
 er Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETT
 A RCC-208)\nEstimated primary completion: 28 November 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07293351
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173751-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07173751)
DESCRIPTION:Pumitamig\, phase 3.\nStudy: ROSETTA Breast-01: The Effects and
  Safety of Pumitamig in Patients With Triple-Negative Breast Cancer\nEstim
 ated primary completion: December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07173751
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221357-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20300202
DTEND;VALUE=DATE:20300203
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT07221357)
DESCRIPTION:Pumitamig\, phase 2/3.\nStudy: A Study to Evaluate the Safety a
 nd Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizum
 ab in Combination With Chemotherapy in Participants With Previously Untrea
 ted\, Unresectable\, or Metastatic Colorectal Cancer\nEstimated primary co
 mpletion: 2 February 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07221357
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953089-2414@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Elfetabart drozuntecan: Phase 2 readout est. (NCT06953089)
DESCRIPTION:Elfetabart drozuntecan\, phase 2.\nStudy: DB-1311 in Combinatio
 n With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06953089
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361497-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20300918
DTEND;VALUE=DATE:20300919
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361497)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradia
 tion Therapy in Participants With Unresectable Stage III Non-small Cell Lu
 ng Cancer (NSCLC) (ROSETTA Lung-201)\nEstimated primary completion: 18 Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 361497
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221149-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20301108
DTEND;VALUE=DATE:20301109
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT07221149)
DESCRIPTION:Pumitamig\, phase 2/3.\nStudy: A Study to Evaluate the Safety a
 nd Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab
  in Combination With Chemotherapy in Participants With Previously Untreate
 d Advanced or Metastatic Gastric\, Gastroesophageal Junction\, or Esophage
 al Adenocarcinoma (ROSETTA Gastric-204)\nEstimated primary completion: 8 N
 ovember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitam
 ig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7221149
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079631-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07079631)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Test if an I
 nvestigational Treatment Called BNT314 When Used in Combination With Anoth
 er Investigational Treatment Pumitamig (BNT327) and Chemotherapy\, is Bene
 ficial and Safe for Patients With Advanced Colorectal Cancer\nEstimated pr
 imary completion: December 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07079631
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365995-2414@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Elfetabart drozuntecan: Phase 3 readout est. (NCT07365995)
DESCRIPTION:Elfetabart drozuntecan\, phase 3\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: A Phase III Trial of BNT324 Versus Docetaxel 
 in Metastatic Castration-resistant Prostate Cancer\nEstimated primary comp
 letion: February 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07365995
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, Drug Levels\, and Preliminary Efficacy of BMS-986507 Combi
 nations in Adult Participants With Advanced Solid Tumors\nEstimated primar
 y completion: 26 February 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Pumitamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361510-1990@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361510)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participa
 nts With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L
 1 ≥ 50%. (ROSETTA Lung-202)\nEstimated primary completion: 14 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07361510
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
